The in-vitro activity of cefdinir (FK482), a new oral cephalosporin

Abstract

The in-vitro activity of cefdinir (FK482), an orally absorbed aminothiazolyl cephalosporin, was compared with that of cefuroxime, cefixime, cephalexin, cefaclor and co-amoxiclav. Cefdinir was highly active against Staphylococcus aureus, inhibiting 90% of strains at 0·03 mg/l. The respiratory pathogens Haemophilus influenzae, Streptococcus pneumroniae, and Moraxella catarrhalis were also susceptible (MIC⁹⁰ ≤ 1 mg/L). The common members of the Entetobactcriaceae were susceptible (MIC⁹⁰ ≤ 1 mg/L), but those possessing chromosomal β-lactamases were more resistant. Cefdinir appeared highly stable to the TEM-1 and SHV-1 β-lactamases with only relatively minor degree of hydrolysis being seen with TEM-3, -5 and -9.